• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by USANA Health Sciences Inc.

    6/20/25 2:47:13 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    11-K 1 usanahealthsciences-202411k.htm 11-K Document


     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     


    FORM 11-K
     

     
    ☒ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2024 

    or
     
    ☐TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     For the transition period from ___________ to ____________
     
    Commission file number: 001-35024
     
     
     
    A. Full title of the plan and the address of the plan, if different from that of the issuer named below:
     
    USANA HEALTH SCIENCES 401(k) PLAN
     
     
    B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
     
    USANA HEALTH SCIENCES, INC.
    3838 West Parkway Blvd.
    Salt Lake City, Utah 84120

     


     
     





     
     
    USANA HEALTH SCIENCES 401(k) PLAN
    FORM 11-K
    For the Year Ended December 31, 2024
     
    INDEX
     
     
     Page
      
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
     
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4
    Schedule of Assets (Held at End of Year)*
    8
    Exhibit
    9
    Signature
    10
     
     
    * Other supplementary schedules required by section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.






    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
     

    To the Plan Administrators and Plan Participants of
    USANA Health Sciences 401(k) Plan

    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of the USANA Health Sciences 401(k) Plan (the Plan) as of December 31, 2024 and 2023, and the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes to financial statements (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information
    The supplemental information contained in the schedule of assets (held at end of year) has been subjected to audit procedures performed in conjunction with the audit of the Plan's financial statements. The supplemental information is the responsibility of the Plan's management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ Tanner LLC


    We have served as the Plan’s auditor since 2004.


    Salt Lake City, Utah
    June 20, 2025
        
     


    1



    USANA HEALTH SCIENCES 401(k) PLAN
    Statements of Net Assets Available for Benefits
     

    December 31,
    20242023
    Assets:
    Investments, at fair value:
    Mutual funds$115,197,895 $103,501,793 
    USANA Health Sciences, Inc. Stock Fund2,462,308 3,572,552 
    Collective investment fund6,264,482 3,130,658 
    Total investments123,924,685 110,205,003 
    Receivables:
    Notes receivable from participants2,400,566 2,165,709 
    Total receivables2,400,566 2,165,709 
    Net assets available for benefits$126,325,251 $112,370,712 

     
     
    The accompanying notes are an integral part of these statements.
     



    2


    USANA HEALTH SCIENCES 401(k) PLAN
    Statement of Changes in Net Assets Available for Benefits
    Year Ended December 31, 2024

    2024
    Additions:
    Investment income:
    Net appreciation in fair value of investments$11,753,939 
    Interest and dividends4,312,394 
    Investment income16,066,333 
    Interest on notes receivable from participants161,104 
    Contributions:
    Participants6,393,151 
    Employer2,513,203 
    Rollovers586,364 
    Total contributions9,492,718 
    Total additions25,720,155 
    Deductions:
    Benefits paid to participants(11,566,896)
    Administrative expenses(198,720)
    Total deductions(11,765,616)
    Increase in net assets available for benefits13,954,539 
    Net assets available for benefits:
    Beginning of the year112,370,712 
    End of the year$126,325,251 
     

     
     
    The accompanying notes are an integral part of these statements.
     


    3


    USANA HEALTH SCIENCES 401(k) PLAN
    NOTES TO FINANCIAL STATEMENTS
     
    NOTE A – DESCRIPTION OF THE PLAN
     
    The following description of the USANA Health Sciences 401(k) Plan (the “Plan”) provides only general information. Participants and other financial statement users should refer to the Plan document, as amended, and summary plan description for a more complete description of the Plan’s provisions.
     
    1.General
     
    The Plan is a defined contribution plan covering substantially all United States non-union employees of USANA Health Sciences, Inc. (collectively, the “Company” or the “Employer”) who have completed one month of service and are age 18 or older. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, and permits traditional 401(k) deferrals (pre-tax) as well as Roth 401(k) deferrals (after-tax). 

    The trustee for the 2024 and 2023 Plan year is Fidelity Management Trust Company (“Fidelity” or “Trustee”) and the recordkeeping functions were performed by Fidelity Workplace Services, LLC.

    On December 29, 2022, the Setting Every Community Up for Retirement Enhancement Act 2.0 ("SECURE 2.0") was signed into law, continuing the themes and reforms that began with the 2019 CARES Act. Many of the provisions of SECURE 2.0 became effective in 2024, including mandatory and optional provisions impacting defined contribution plans. The plan has adopted all of the applicable mandatory provisions, including increasing the age at which required minimum distributions start, eliminating the required minimum distributions for Roth 401(k) accounts, and new spousal beneficiary rules.
     
    2.Contributions
     
    Each year participants may elect to contribute up to 75 percent of their annual compensation subject to certain limits as defined in the Plan. Participant contributions are limited by the Internal Revenue Code, which established a maximum contribution of $23,000 ($30,500 for participants aged 50 or older) for the year ended December 31, 2024. Participants may elect to make pre-tax contributions and/or after-tax elective contributions into their accounts. Participants may also contribute rollover amounts representing distributions from certain other defined benefit or defined contribution plans. Under the safe harbor and certain other provisions of the Plan, eligible employees who have not made an affirmative election to defer or not defer will have deferrals withheld in the amount of six percent of their compensation, to be invested in the appropriate target date retirement fund. Participants may direct their investments into one or more of the investment options offered by the Plan, with no more than 25 percent of their investment allocations directed into shares of the USANA Health Sciences, Inc. Stock Fund (“Stock Fund”).
     
    The Company provides a matching contribution equal to 100 percent of the first one percent of a participant’s compensation that is contributed as an elective deferral by the participant, and 50 percent of elective deferrals between one and six percent of the participant’s compensation. The Company’s board of directors may also authorize additional contributions to the Plan. No additional contributions were authorized during the year ended December 31, 2024.
     
    3.Participant accounts
     
    Self-directed individual investment accounts are maintained for each Plan participant. Each participant’s account is adjusted for the participant’s contributions and allocations of (a) the Company’s contributions, (b) investment gains or losses, (c) interest and dividends, and (d) administrative expenses. The allocation of the Company’s discretionary contributions and forfeitures is based on each participant’s contribution, as defined by the Plan. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.
     
    4.Vesting
     
    Participants are fully vested in their voluntary contributions, including any net investment income on those contributions. The Company’s matching contributions fully vest at the end of two years of service. Non-elective employer contributions vest 25% at the end of each year and are fully vested after four years of service. 

    5.Notes receivable from participants
     
    A participant may borrow a minimum of $1,000 up to a maximum of three loans that in the aggregate are equal to the lesser of $50,000 or 50 percent of his or her vested account balance. Loans are secured by the balances in the participants’ accounts and bear interest at rates ranging from 4.25 percent to 9.50 percent, which rates were commensurate with prevailing rates at the time of loan origination. Principal and interest are paid ratably through payroll deductions. Loans are re-paid over a five-year period, unless the loans were used to purchase a principal residence, in which case the payback period may not exceed 30 years. As of December 31, 2024, the Plan had outstanding loans to participants with maturities ranging from 2025 through 2054.


    4


    USANA HEALTH SCIENCES 401(k) PLAN
    NOTES TO FINANCIAL STATEMENTS - CONTINUED


    NOTE A – DESCRIPTION OF THE PLAN – CONTINUED
     
    6.Benefits paid to participants
     
    On termination of service due to death, permanent disability, or retirement, a participant or beneficiary may receive a lump-sum amount equal to the value of the participant’s vested interest in his or her account. For termination of service due to other reasons, the Plan will automatically make a lump-sum distribution of the value of the participant’s vested interest in his or her account where the account balance is less than $5,000. Hardship withdrawals are allowed for participants incurring a “specific and heavy financial need,” as defined by the Plan. Hardship withdrawals are strictly regulated under the Internal Revenue Code and the regulations thereunder, and a participant must exhaust all available loan options and available distributions prior to requesting a hardship withdrawal. 

    7.Forfeited accounts
    Forfeited accounts related to the Company’s matching contributions may be used to pay any administrative expenses or used to reduce any future Employer matching contributions. The table below provides a reconciliation of the balance of forfeited accounts as of and for the year ended December 31, 2024.

     
    Balance as of December 31, 2023$81,054 
    Forfeitures119,909
    Employer matching contributions(27,043)
    Earnings on forfeited account balance6,013
    Administrative expenses(5,746)
    Balance as of December 31, 2024$174,187 

    During the year ended December 31, 2024, $27,043 of forfeitures were used to reduce Employer matching contributions and $5,746 forfeitures were used to pay administrative expenses.

    8.Expenses
     
    The Company, as the Plan Sponsor, paid all administrative expenses during the year ended December 31, 2024, except for $198,720.
     
    NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
     
    1.Basis of accounting
     
    The financial statements of the Plan are presented using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
     
    2.Use of estimates
     
    The preparation of financial statements in conformity with U.S. GAAP requires Plan management to make estimates and assumptions that affect certain reported amounts of net assets available for benefits at the date of the financial statements, the changes in net assets available for benefits during the reporting period and, when applicable, the disclosure of contingent assets and liabilities at the date of the financial statements. Key estimates include determination of the fair value of investments. Actual results may differ from estimates and assumptions made.

    5


    USANA HEALTH SCIENCES 401(k) PLAN
    NOTES TO FINANCIAL STATEMENTS - CONTINUED
     
    NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES – CONTINUED
     
    3.Investment valuation and income recognition
     
    The Plan’s investments are stated at fair value. Quoted market prices are used to value investments in shares of mutual funds and the Stock Fund. Units of the collective investment fund are valued at net asset value, which approximates fair value, using daily market information. Net appreciation (depreciation) caused by fluctuations in the value of investments is reflected in the statement of changes in net assets available for benefits. Amounts invested may earn interest and dividends, which in turn are reinvested.
     
    Purchases and sales of securities are recorded on a trade-date basis. Income from interest is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Earnings and losses within each fund are allocated to participants based on their proportionate shares in the fund.
     
    In general, the Plan’s securities are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of net assets available for benefits.
     
    4.Notes receivable from participants
     
    Notes receivable from participants represent participant loans and are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. As of December 31, 2024 and December 31, 2023, no allowances for credit losses had been recorded. If a participant ceases to make loan repayments and the Plan Administrators deem the note receivable from a participant to be a distribution, the note receivable balance is reduced and a benefit payment is recorded.
     
    5.Benefits paid to participants
     
    Benefits are recorded when paid. As of December 31, 2024 and December 31, 2023, there were no distributions that had been requested but not paid.
     
    NOTE C – FAIR VALUE MEASUREMENTS
     
    The Plan reports investments in accordance with established authoritative guidance, which requires a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.
     
    The three levels are defined as follows:
     
     ●Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.

     ●Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.

     ●Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.
     
    Mutual funds are valued at the total market value of the underlying assets based upon the publicly quoted price of each fund multiplied by the respective number of units held as of the measurement date and are classified as Level 1 investments.
     
    The Stock Fund is a unitized stock fund consisting primarily of the Company’s common stock, and cash for daily liquidity purposes. The Stock Fund is classified as Level 1, as the total fair value is equal to the quoted market value of total common stock plus the carrying amount of cash, which approximates fair value. The cash balance held by the Plan was $1,068 and $980 as of December 31, 2024 and December 31, 2023, respectively.
     
    In accordance with Subtopic 820-10, the collective investment fund is measured using the net asset value per unit as a practical expedient and is therefore not classified in the fair value hierarchy.
     
    Redemption frequency for the collective investment fund is immediate, contains no unfunded commitments, and has no redemption restrictions.
    6





    USANA HEALTH SCIENCES 401(k) PLAN
    NOTES TO FINANCIAL STATEMENTS - CONTINUED

    NOTE D – EXEMPT PARTY-IN-INTEREST TRANSACTIONS
     
    Plan assets include common stock of the Company.  Transactions with respect to shares of the Company’s common stock qualify as party-in-interest transactions.  As of December 31, 2024 and December 31, 2023, the Plan held 68,577 shares of the Company’s common stock in the Stock Fund with a value of $35.89 per share, and 66,634 shares of the Company’s common stock in the Stock Fund with a value of $53.60 per share, respectively.
     
    Notes receivable from participants as of December 31, 2024 and December 31, 2023, were $2,400,566 and $2,165,709, respectively. Notes receivable are considered party-in-interest transactions. Interest income pertaining to notes receivable from participants totaled $161,104 for 2024.
     
    Certain Plan investments are shares in registered investment company funds managed by Fidelity Investments, an affiliate of the Trustee as defined by the Plan, and therefore, these transactions qualify as party-in-interest transactions.
     
    NOTE E – PLAN TERMINATION
     
    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue the Company’s contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, participants become 100 percent vested in their accounts.

    NOTE F – TAX STATUS
     
    The Plan has adopted a non-standardized prototype plan for which the Internal Revenue Service (“IRS”) has issued a favorable opinion letter covering the qualification of the Plan. The Plan Administrators and the Plan’s tax counsel do not anticipate that changes in the Plan after the date of the IRS opinion letter will affect the qualified and tax-exempt status of the Plan. Accordingly, the financial statements of the Plan do not include provisions, assets or liabilities related to income taxes.
     
    U.S. GAAP requires management to evaluate income tax positions taken by the Plan and to recognize an income tax liability if the Plan has taken an uncertain tax position that more likely than not would not be sustained upon examination by taxing authorities. The Plan Administrators analyzed the tax positions taken by the Plan and have concluded that as of December 31, 2024 and December 31, 2023, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by tax jurisdictions for tax years for which the applicable statutes of limitations have not expired; however, there are currently no audits for any tax periods in progress.
     
     

    7


    USANA HEALTH SCIENCES 401(k) PLAN
    SUPPLEMENTAL INFORMATION
    Employer Identification Number: 87-0500306
    Plan Number: 001
    SCHEDULE H, PART IV, Line 4(i)
    SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    As of December 31, 2024
     
    ( a )( b )( c )( d )( e )
    IDENTITY OF ISSUE, BORROWER, LESSOR, OR SIMILAR PARTYDESCRIPTION OF INVESTMENTCOSTCURRENT VALUE
    *Fidelity® 500 Index FundMutual funds**$14,893,033 
    *Fidelity® Large Cap Growth Index FundMutual funds**13,173,698 
    American Funds 2050 Target Date Retirement Fund® Class R-6Mutual funds**11,935,108 
    American Funds Washington Mutual Investors Fund® Class R-6Mutual funds**8,728,376 
    American Funds 2045 Target Date Retirement Fund® Class R-6Mutual funds**7,625,070 
    American Funds 2040 Target Date Retirement Fund® Class R-6Mutual funds**7,584,957 
    American Funds 2035 Target Date Retirement Fund® Class R-6Mutual funds**6,291,363 
    American Funds 2055 Target Date Retirement Fund® Class R-6Mutual funds**5,360,334 
    American Funds 2030 Target Date Retirement Fund® Class R-6Mutual funds**5,311,805 
    PGIM Total Return Bond Fund Class R-6Mutual funds**5,080,872 
    American Funds American Balanced Fund® Class R-6Mutual funds**3,777,946 
    American Funds SMALLCAP World Fund® Class R-6Mutual funds**3,504,317 
    International Diversification Fund Class R-6Mutual funds**2,864,892 
    *Fidelity® Mid Cap Index FundMutual funds**2,713,901 
    *Fidelity® Small Cap Index FundMutual funds**2,316,066 
    Carillon Eagle Mid Cap Growth Fund Class R-6Mutual funds**2,300,002 
    American Funds 2060 Target Date Retirement Fund® Class R-6Mutual funds**2,141,869 
    American Funds New World Fund® Class R-6Mutual funds**1,963,581 
    Janus Henderson Triton Fund Class IMutual funds**1,508,471 
    Victory Sycamore Established Value Fund Class R-6Mutual funds**1,437,366 
    American Funds 2025 Target Date Retirement Fund® Class R-6Mutual funds**1,102,195 
    Undiscovered Managers Behavioral Value Fund Class LMutual funds**1,007,974 
    Principal Real Estate Securities Fund Institutional ClassMutual funds**989,573 
    *Fidelity® Total International Index FundMutual funds**805,183 
    Principal Diversified Real Asset Fund Class R-6Mutual funds**520,669 
    American Funds 2020 Target Date Retirement Fund® Class R-6Mutual funds**236,874 
    American Funds 2015 Target Date Retirement Fund® Class R-6Mutual funds**8,798 
    American Funds 2010 Target Date Retirement Fund® Class R-6Mutual funds**8,199 
    *Fidelity® Government Money Market FundMutual funds**5,403 
    115,197,895 
    *USANA Health Sciences, Inc. Stock FundStock Fund**2,462,308 
    Galliard Stable Return Fund CCollective investment fund**6,264,482 
    *Notes receivable from participantsLoans with interest rates ranging from 4.25% to 9.50%, with maturities through 2054N/A2,400,566 
    $126,325,251 
    *Party-in-interest
    **Column (d) cost information is not presented as these investments are participant directed.
    See accompanying Report of Independent Registered Public Accounting Firm
     
    8


    EXHIBIT
     
    Exhibit
    Number
     Description
    23.1 
    Consent of Independent Registered Public Accounting Firm (filed herewith)
     


    9


    SIGNATURE
     
    The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date:
    June 20, 2025
     
     
     
      
     USANA Health Sciences 401(k) Plan
      
     /s/ G. Douglas Hekking
     G. Douglas Hekking
     
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    Plan Sponsor
     
     
    10
    Get the next $USNA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C

      7/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules Second Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

      7/2/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Invites All to Discover Freedom in July

      SALT LAKE CITY, July 2, 2025 /PRNewswire/ -- With freedom as a universal desire being celebrated this month, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE:USNA), is inspiring individuals and families to celebrate freedom on a personal level for self-care. Research reveals countless global celebrations honoring freedom—from America's Independence Day on July 4 to the unifying spirit of Canada Day on July 1 and numerous others around the world. "Freedom is more than a national observance; it's deeply personal, complex and transformational," said Guest, author of

      7/2/25 7:37:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    SEC Filings

    See more
    • USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      7/22/25 4:06:41 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      7/1/25 11:54:40 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 11-K filed by USANA Health Sciences Inc.

      11-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      6/20/25 2:47:13 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fleming John Turman sold $14,829 worth of shares (500 units at $29.66), decreasing direct ownership by 11% to 4,200 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      6/10/25 12:35:13 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • CHIEF OPERATING OFFICER Noot Walter sold $190,568 worth of shares (6,291 units at $30.29), closing all direct ownership in the company (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/29/25 10:24:07 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Ding Xia

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:40:18 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C

      7/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules Second Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

      7/2/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care